Balyasny Asset Management
EVMN

Balyasny Asset Management’s Evommune Inc EVMN Stock Holding History

Balyasny Asset Management’s Portfolio EVMN Stock Details EVMN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-65,000
Closed -$1.11M – 3710
2025
Q4 		$1.11M Buy
+65,000
New +$1.22M ﹤0.01% 2140

Other funds holding EVMN

EFM
EQT Fund Management Luxembourg $1.02B AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
AP
Andera Partners Paris $206M AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
SCP
SymBiosis Capital Partners Bentonville, Arkansas $52.8M AUM
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Balyasny Asset Management's EVMN Position: Q1 2026 in Review

Balyasny Asset Management sold out of Evommune Inc (EVMN) in Q1 2026, closing a stake of 65,000 shares — an estimated $1.11M sold.

Balyasny Asset Management first reported a position in EVMN in Q4 2025 and held it in 1 quarter. The position peaked at $1.11M in Q4 2025. 84 funds tracked by Wall St. Rank hold EVMN as of Q1 2026.

  • Balyasny Asset Management reported no remaining Evommune Inc position as of Q1 2026 after selling out during the quarter.
  • Balyasny Asset Management sold 65,000 Evommune Inc shares in Q1 2026, an estimated $1.11M.
  • Balyasny Asset Management first reported a position in Evommune Inc in Q4 2025 and held it in 1 quarter.
  • Balyasny Asset Management's Evommune Inc position peaked at $1.11M in Q4 2025.
  • 84 funds tracked by Wall St. Rank held Evommune Inc as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.